GlassScriptPhysician profile
Oleg Chebotarev
NPI 1780647552
$22,263.16
in general payments reported to CMS, 2019-2025
30 companies · $6,501 in 2025
The $6,501 reported for 2025 was more than what 93% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,121 · 2020: $745 · 2021: $1,064 · 2022: $240 · 2023: $4,951 · 2024: $7,643 · 2025: $6,501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $2,200 · Travel and Lodging: $1,144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,750.00 |
| Food and Beverage | $2,200.13 |
| Travel and Lodging | $1,144.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $12,167.46 | 2019-2025 | Farxiga, Lokelma |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $6,584.54 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $1,031.32 | 2019-2022 | |
| Boston Scientific Corporation | $633.78 | 2019-2025 | Watchman Flx, Watchman, Watchman Access System |
| Pfizer INC. | $343.15 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $189.21 | 2019-2025 | Camzyos |
| Amarin Pharma, INC. | $156.68 | 2019-2020 | |
| Genzyme Corporation | $149.74 | 2019-2021 | |
| Gilead Sciences, INC. | $139.06 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.47 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $100.78 | 2019-2022 | |
| Amgen INC. | $94.06 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $85.26 | 2021-2025 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $57.88 | 2023 | Inpefa |
| Sanofi-Aventis U.S. LLC | $45.07 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $43.58 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $39.22 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $30.32 | 2020-2025 | Opsumit |
| Regeneron Healthcare Solutions, INC. | $29.13 | 2019 | |
| Daiichi Sankyo INC. | $28.81 | 2025 | Injectafer |
| Abbott Laboratories | $26.83 | 2019-2020 | |
| Bracco Diagnostics INC. | $23.88 | 2022 | |
| Biomerieux INC | $23.12 | 2021 | |
| Cook Medical LLC | $22.82 | 2024 | Hemospray |
| Terumo Medical Corporation | $22.17 | 2021 | |
| Esperion Therapeutics, INC. | $14.95 | 2021 | |
| Vifor Pharma, INC. | $14.52 | 2021 | |
| Scpharmaceuticals INC. | $14.27 | 2025 | |
| Arbor Pharmaceuticals, INC. | $13.94 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oleg Chebotarev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.